Werbung
Werbung

NMRA

NMRA logo

Neumora Therapeutics, Inc. Common Stock

2.22
USD
Gesponsert
-0.11
-4.59%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

2.25

+0.03
+1.17%

NMRA Ergebnisberichte

Positives Überraschungsverhältnis

NMRA übertreffen die 5 der letzten 9Schätzungen.

56%

Nächster Bericht

Datum des nächsten Berichts
27. Apr. 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.33
Implizierte Änderung von Q3 25 (Revenue/ EPS)
--
/
+3.13%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
--
/
-10.81%

Neumora Therapeutics, Inc. Common Stock earnings per share and revenue

On 06. Nov. 2025, NMRA reported earnings of -0.32 USD per share (EPS) for Q3 25, beating the estimate of -0.34 USD, resulting in a 5.99% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.53% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.33 USD, with revenue projected to reach -- USD, implying an increase of 3.13% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Neumora Therapeutics, Inc. Common Stock reported EPS of -$0.32, beating estimates by 5.99%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.53%, changed from $2.62 before the earnings release to $2.58 the day after.
The next earning report is scheduled for 27. Apr. 2026.
Based on 10 analysts, Neumora Therapeutics, Inc. Common Stock is expected to report EPS of -$0.33 and revenue of -- for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung